NEW YORK (GenomeWeb) - Veracyte today announced after the close of the market that revenues for its first quarter rose 50 percent on sales of its Afirma gene expression classifier (GEC) tests.

For the three months ended March 31, 2015, the South San Francisco, California-based molecular diagnostics company said that revenues increased to $11.2 million from $7.5 million a year ago, beating the average Wall Street expectation of $10.8 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.